Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.

Hannelius, Ulf; Beam, Craig A; Ludvigsson, Johnny

Hannelius, Ulf; Beam, Craig A; Ludvigsson, Johnny.

Affiliation

Hannelius U; Diamyd Medical AB, Kungsgatan 29, 111 56, Stockholm, Sweden. ulf.hannelius@diamyd.com.
Beam CA; Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.
Ludvigsson J; Crown Princess Victoria Children's Hospital, Linköping, Sweden. Johnny.Ludvigsson@liu.se.

Diabetologia ; 63(10): 2177-2181, 2020 10.

Article in En | MEDLINE | ID: mdl-32754804

Subject(s)

Adjuvants, Immunologic/therapeutic use; Aluminum Hydroxide/therapeutic use; C-Peptide/metabolism; Desensitization, Immunologic/methods; Diabetes Mellitus, Type 1/therapy; Glutamate Decarboxylase/therapeutic use; HLA-DQ Antigens/genetics; HLA-DR3 Antigen/genetics; Diabetes Mellitus, Type 1/genetics; Diabetes Mellitus, Type 1/immunology; Diabetes Mellitus, Type 1/metabolism; HLA-DR4 Antigen/genetics; Haplotypes; Humans; Immunotherapy/methods; Randomized Controlled Trials as Topic; Treatment Outcome

Key words

Antigen-specific; Autoimmune diabetes; C-peptide; GAD; Glutamic acid decarboxylase; HLA; Immunotherapy; Type 1 diabetes; Vaccine

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: C-Peptide / HLA-DQ Antigens / HLA-DR3 Antigen / Adjuvants, Immunologic / Desensitization, Immunologic / Diabetes Mellitus, Type 1 / Aluminum Hydroxide / Glutamate Decarboxylase Type of study: Clinical_trials / Diagnostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Diabetologia Year: 2020 Type: Article Affiliation country: Sweden

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google